ecteinascidin 743 has been researched along with Adenocarcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avendaño, C; Cuesta, Ede L; González, JF; Manguan-García, C; Ortín, I; Perona, R | 1 |
| Allavena, P; Belli, C; Cangi, MG; Cappio, S; Ceraulo, D; D'Incalci, M; Doglioni, C; Dugnani, E; Garassini, G; Maggiora, P; Piemonti, L; Porcu, L; Reni, M; Zucchetti, M | 1 |
1 trial(s) available for ecteinascidin 743 and Adenocarcinoma
| Article | Year |
|---|---|
Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Deoxycytidine; Dioxoles; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2016 |
1 other study(ies) available for ecteinascidin 743 and Adenocarcinoma
| Article | Year |
|---|---|
Pyrazino[1,2-b]isoquinolines: synthesis and study of their cytostatic and cytotoxic properties.
Topics: Adenocarcinoma; Apoptosis; Cell Cycle; Cell Division; Cell Line, Tumor; Cytostatic Agents; DNA Damage; G1 Phase; G2 Phase; HT29 Cells; Humans; Inhibitory Concentration 50; Isoquinolines; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; S Phase; Structure-Activity Relationship | 2008 |